A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant
osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy
alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

Inclusion Criteria:

- Male or female, at least 18 years of age. For patients aged <20 years and enrolled in
Japan, a written informed consent should be obtained from the patient and his or her
legally acceptable representative

- Histologically or cytologically documented non-squamous NSCLC with completely
resectable (Stage II - IIIB N2) disease (according to Version 8 of the IASLC Cancer
Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016]).

- Complete surgical resection of the primary NSCLC must be deemed achievable, as
assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in
oncologic procedures).

- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at enrolment, with no
deterioration over the previous 2 weeks prior to baseline or day of first dosing

- A tumour which harbours one of the 2 common EGFR mutations known to be associated with
EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR
mutations (eg., T790M, G719X, Exon20 insertions, S7681 and L861Q).

Exclusion Criteria:

- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required
steroid treatment, or any evidence of clinically active ILD.

- History of another primary malignancy (including any known or suspected synchronous
primary lung cancer), except for the following: Malignancy treated with curative
intent and with no known active disease ≥2 years before the first dose of
investigational product (IP) and of low potential risk for recurrence; Adequately
treated non-melanoma skin cancer or lentigo malignancy without evidence of disease;
Adequately treated carcinoma in situ without evidence of disease; Any synchronous
Stage IA primary lung cancer that is ≤2 cm and planned to be resected during surgery
for the Stage II to IIIB N2 lung tumour.

- Patients who have pre-operative radiotherapy treatment as part of their care plan

- Mixed small cell and NSCLC histology

- Stages I, IIIB N3, IIIC, IVA, and IVB NSCLC

- T4 tumours infiltrating the great vessels, the carina, the trachea, the oesophagus,
the heart, and/or the vertebral body; and/or any bulky N2 disease.

- Patients who are candidates to undergo only segmentectomies or wedge resections

- Prior treatment with any systemic anti-cancer therapy for NSCLC including
chemotherapy, biologic therapy, immunotherapy, or any investigational drug

- Prior treatment with EGFR-TKI therapy

- Current use of (or unable to stop use prior to receiving the first dose of study
treatment) medications or herbal supplements known to be strong inducers of cytochrome
P450 (CYP) 3A4 (at least 3 weeks prior)